Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × AFM13 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Hodgkin Disease 3 Lymphoma, T-Cell, Peripheral 2 Lymphoma, T-Cell 2 Recurrence 1 Mycosis Fungoides 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, B-Cell 1 Lymphoma 1

Interventions

Cyclophosphamide 138 Dexamethasone 119 Rituximab 76 fludarabine 66 Lenalidomide 64 Cytarabine 60 Gemcitabine 55 Bortezomib 53 fludarabine phosphate 52 venetoclax 47 pembrolizumab 46 Etoposide 46 Paclitaxel 45 Carboplatin 45 pomalidomide 44 Cisplatin 44 Peripheral Blood Stem Cell Transplantation 40 Radiotherapy 38 Filgrastim 38 Busulfan 33 Bevacizumab 33 Melphalan 32 carfilzomib 30 Calcium Dobesilate 30 Methotrexate 29 Cyclosporine 29 Azacitidine 28 Mycophenolic Acid 27 Nivolumab 26 Bendamustine Hydrochloride 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05883449 2025-08-20

LuminICE-203

Affimed GmbH

Phase 2 Terminated

25 enrolled 21 charts

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon ⚡